Company intelligence / Profile preview

Dualsystems Biotech

Schlieren, Zurich, Switzerlanddualsystems.com ↗

Ownership: Private
Development stage: Commercial

Overview

Dualsystems Biotech provides proteomics services using its proprietary LRC-TriCEPS™ platform to identify drug targets and off-targets on living cells. Their technology has enabled discoveries such as novel cellular factors involved in Zika virus infection and new receptor-ligand interactions that are difficult to detect with traditional methods. The company collaborates with academic institutions and industry clients globally.

Therapeutic areas: Other
Modalities: ProteinPeptidesSmall molecule
Industry: Drug Discovery Services

Partnerships

University Hospital of Lausanne/CHUVLund University Diabetes Centre

Beyond the preview

Go deeper on Dualsystems Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dualsystems Biotech.

Explore the full profile